CT-721

• UNSPSC Description:

  CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities[1]. CT-721 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ct-721.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC=C(NC(C2=CC=C([C@@H](N3CCN(C)CC3)CC4)C4=C2)=O)C=C1C#CC5=CN=C6N5N=C(Cl)C=C6

• Molecular Weight:

  525.04

• References & Citations:

  [1]Sun Y, et al. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia. J Cancer. 2017 Aug 23;8(14):2774-2784.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1388710-60-8